A phase I-II study of RAD001 [everolimus] in combination with imatinib (Glivec/Gleevec) in patients with chronic myelogenous leukemia (CML) in chronic phase who are not in complete cytogenetic response to imatinib-alone at study entry.

Trial Profile

A phase I-II study of RAD001 [everolimus] in combination with imatinib (Glivec/Gleevec) in patients with chronic myelogenous leukemia (CML) in chronic phase who are not in complete cytogenetic response to imatinib-alone at study entry.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2013

At a glance

  • Drugs Everolimus; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Oct 2009 Planned number of patients changed from 4 to 50 as reported by ClinicalTrials.gov.
    • 07 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top